Pleco Therapeutics

Executive Summary

Pleco Therapeutics is a Dutch private biopharmaceutical company pioneering Plecoid™ therapies, a novel small-molecule platform designed to potentiate the efficacy of existing cancer treatments. Founded in 2016 and headquartered in Amsterdam, the company's mission is to extend patient lifespan and improve quality of life by addressing treatment resistance and enhancing therapeutic outcomes. Plecoid™ agents work by modulating cellular pathways to make cancer cells more susceptible to chemotherapies and targeted agents, potentially allowing for lower doses and reduced side effects. While specific pipeline details and development stage are not publicly disclosed, the company's focus on drug combination strategies positions it within the high-need area of oncology adjunct therapies.

Upcoming Catalysts (preview)

• Q2 2027First-in-human Phase 1 trial initiation for lead Plecoid™ candidate60% success
• H2 2026Announcement of strategic partnership or licensing deal with a larger oncology-focused pharmaceutical company30% success
• Q4 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal or major medical conference70% success